Dezapelisib

DB16137InvestigationalSmall molecule

Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/refractory Hodgkin Lymphoma).

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Curator reviewed
Formula / weight: C₂₀H₁₆FN₇OS · 421.45 g/mol (avg)
Code names: INCB-040093 · INCB-40093

Resolves to

Compound

UNII2K59L7G59MCAS1262440-25-4ChEMBLCHEMBL2216863

Structure

InChIKeyRSIWALKZYXPAGW-NSHDSACASA-NSMILESC[C@H](NC1=C2N=CNC2=NC=N1)C1=C(C(=O)N2C(C)=CSC2=N1)C1=CC=CC(F)=C1

Targets

O00329PIK3CD

What you can answer from here — as of September 20, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dezapelisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account